Patient Engagement

Program puts a new-and very real-spin on patient nutrition.

FDA's approval of the first-ever digital medicine, while sparking legitimate concerns around ethics and trust, could signal improvements ahead to the much-chronicled woes in drug adherence and compliance.

This article explores the difficult nature of developing drugs for rare diseases and discusses what a pharmaceutical executive can actively do to help increase success.

Mary Lynne Hedley, president and COO of TESARO, talks to Pharm Exec about the company’s innovative approach to responsible drug development and commercialization, and how its theory of putting patients first is translated into practise.

Funso Olufade discusses how solutions such as the new Adherence Package can help increase pharma–patient engagement.

Q&A spotlights the development of one injection device that is helping change the treatment-adherence landscape.

How companies are closing the innovation gap between the lab and the patient, while also creating value for all stakeholders.

Here's to hoping that PhRMA's new public education campaign advances the voice of the patient in its messaging.

How can Pharma balance the need to access to patient data and still respect patient privacy? One approach is to access patients through third-party online communities, writes Peter Houston.

Balancing today’s health data demands and patient privacy is not about new regulations-it’s taking a risk-based approach.

Amid today's growing constituency of cancer survivors, oncology is testing the historic divide in medicine between what’s science and what’s social.

As drugmakers seek engagement, patients are buried in content. Thus, quality and appealing material is a must to grab a share of the narrow bandwidths that patients possess.

Pharma's challenge is to break the cycle of mistrust so that its pioneering work can fully reach patients in need, writes GSK's Murray Stewart.

For those willing to invest in the right capabilities, offering patient services can give pharma companies a tremendous opportunity.

An “how to” primer for life sciences companies on applying end-to-end evidence strategies in demonstrating product value.

Pharm Exec talks to Jane Griffiths, Company Group Chairman, Janssen EMEA, about how the relationship between industry and patients is maturing.

Pharm Exec talks with David Dosa, a leading physician in geriatric medicine, whose famous work with a cat named oscar in end-of-life diagnostics became the stuff of therapeutic legend.

As vital contributors to hospital disaster preparedness, the pharma industry has a role to play in making sure medical networks have what they need to meet the unforeseen, including future disasters.

Rare disease supporters deliver inspiration and optimism-as well as promise of regulatory cooperation.

The key steps to implementing the "patient access" model of the future

AmerisourceBergen believes the power of community begins with talk that gets the blood flowing.

A new IMS study reveals how changes in the design of commercial/employer-based health insurance plans are accelerating the push to higher patient contributions to the cost of prescribed drugs. William Looney reports.

As pharma continues to move towards "beyond the pill" strategies, better understanding of patients' sometimes paradoxical view of disease can help lead to strategies for helping them live more productive lives, writes Nick Hicks.

Nick Hicks looks at the challenges of devising a patient advocacy strategy amid the complex political, cultural and regulatory landscape of Russia and CIS.

While the initiation and management of an access program can be challenging and requires careful assessment and planning, the benefits to patients, healthcare providers and sponsoring companies are immeasurable, writes Rob Fox. “Patients will find you.”In his keynote address at this year’s World Orphan Drug Congress, Henri Termeer, the former CEO, chairman and president of Genzyme reminded the audience that patients will actively seek out companies developing new therapeutics for their unmet medical needs.

A patient has been prescribed a drug, your company’s drug. What next? Is there an app for that?Step back and think about the patient journey to this point. In the course of the joys and trials of day-to-day living, a patient may be afflicted with early symptoms. Be they minor or severe, a patient hopefully receives a diagnosis, often after missed opportunities and wrong turns than can stretch for years.